Most big prescription drug manufacturers anticipate the proposed Medicare International Pricing Index (IPI) model for lowering Part B drug prices would have a substantial, negative effect on research and development in the industry, according to the Pharmaceutical Research and Manufacturers of America.
Seventy-seven percent of PhRMA members responding to a recent internal survey said that if the IPI were to go into...






